Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
Presentations include analytical validation of Myriad’s high-definition tumor informed MRD assay for breast cancer and its Breast Cancer Risk Assessment Tool MyRisk® with RiskScore®
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
Agreement will expand worldwide access and better position Myriad’s GIS as a potential companion diagnostic across multiple potential tumor types
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
SneakPeek®, the first at-home early fetal sex test for use at six weeks, is now available at over 8,800 retail locations nationwide.
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
New sponsored testing program leverages Myriad’s MyChoice Tests for patients with high-grade serous ovarian cancer
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024. Dr. Daneker brings more than 30 years of oncology and precision medicine […]
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx cancer tests
New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood
New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood
